FiercePharmaAsia combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.
The pharmaceutical industry's producers and academic researchers in Japan are actively engaged, despite setbacks experienced by others such as Google, in building a big-data pipeline, this one now including 10 drugmakers and 30 medical institutions.
If China has its way, within another year or two, a repeat of the GlaxoSmithKline and similar scandals will be far less likely, but drugmakers can expect to face a harder sell as a result. The government just completed a comprehensive healthcare reform plan centered on the nation's public-hospital system, but with a reach throughout the medical process.
Payers have put the squeeze on GlaxoSmithKline's top seller Advair, helping sink its sales and send company revenues tumbling. So GSK doesn't want to play with fire by hawking more high-priced meds. Instead, the company's identified a different path to growth, it said Wednesday--and the name of the game is volume.
GlaxoSmithKline will have some questions to answer this week after reporting its first quarterly results with Novartis' former vaccines stable. The company's vaccines unit saw its operating profit plummet and operating margin decline after folding in the Swiss drugmaker's business.
GlaxoSmithKline's respiratory woes continued in Q1, with stateside sales of aging blockbuster Advair sinking 22%. The company has pricing pressure to thank for that slide.
About that ViiV Healthcare spinoff GlaxoSmithKline's been looking at--it's not happening, the pharma giant says.
GlaxoSmithKline is facing sluggish sales in the U.S. and revenue growth that falls behind that of its Big Pharma rivals, not to mention scrutiny for CEO Andrew Witty. So Philip Hampton will have his work cut out for him as he steps into his new role as the company's chairman and attempts to revive the company's lagging fortunes.
Close to 5 years after GlaxoSmithKline signed on to collaborate with the San Raffaele Telethon Institute for Gene Therapy in Italy, the partners have stepped up with a European application to start marketing a gene therapy for extraordinarily rare cases of immune deficiency triggered by ADA-SCID. And its delivery into regulatory hands comes as the gene therapy field has been recoiling from some notable setbacks that have begun to cloud what has been a bullish sector in biotech.
Analysts are suggesting that GlaxoSmithKline is thinking hard about scrapping a plan to reward investors by paying them about £4 billion and instead use money from its deals with Novartis to prop up its dividend, Reuters reports.